



December 22, 2021

BSE Limited

Code: 532321

1st Floor, P J Towers, Dalal Street, Mumbai-400001

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East), Mumbai-400051

Code: Cadilahc

Re.: **Press Release**

Dear Sir / Madam,

Please find enclosed a copy of press release dated December 22, 2021 titled "Zydus Cadila receives tentative approval from USFDA for Pimavanserin Tablets".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully, For, CADILA HEALTHCARE LIMITED

DHAVAL N. SONI **COMPANY SECRETARY**

Encl.: As above



Zydus Cadila receives tentative approval from USFDA for Pimavanserin Tablets

Ahmedabad, 22 December, 2021

Zydus Cadila has received tentative approval from the USFDA to market Pimavanserin Tablets, 10 mg (US RLD: Nuplazid Tablets). Pimavanserin is used to treat the symptoms of a certain mental/mood disorder (psychosis) that might occur with Parkinson's disease. It helps lessen symptoms such as seeing or hearing things that are not there (hallucinations) and false beliefs (delusions).

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 325 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The group employs over 23000 people worldwide and is dedicated to creating healthier communities globally.
